Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to 0.3%.

  • Entrada Therapeutics' Return on Capital Employed fell 4100.0% to 0.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.3%, marking a year-over-year decrease of 4100.0%. This contributed to the annual value of 0.1% for FY2024, which is 1200.0% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Return on Capital Employed of 0.3% as of Q3 2025, which was down 4100.0% from 0.21% recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Return on Capital Employed peaked at 0.2% during Q2 2024, and registered a low of 0.4% during Q4 2022.
  • For the 4-year period, Entrada Therapeutics' Return on Capital Employed averaged around 0.09%, with its median value being 0.06% (2023).
  • Its Return on Capital Employed has fluctuated over the past 5 years, first skyrocketed by 4500bps in 2024, then tumbled by -4200bps in 2025.
  • Entrada Therapeutics' Return on Capital Employed (Quarter) stood at 0.4% in 2022, then surged by 98bps to 0.01% in 2023, then skyrocketed by 1045bps to 0.09% in 2024, then plummeted by -418bps to 0.3% in 2025.
  • Its Return on Capital Employed stands at 0.3% for Q3 2025, versus 0.21% for Q2 2025 and 0.01% for Q1 2025.